EPDS Should Be the Primary Screening Tool for Postpartum Depression
The Edinburgh Postnatal Depression Scale (EPDS) is the recommended primary screening tool for postpartum depression over the PHQ-2, based on superior psychometric validation and a Class A recommendation from the most rigorous systematic review available. 1
Evidence Supporting EPDS as First-Line
The 2022 JAMA Network Open systematic review using COSMIN (Consensus-Based Standards for the Selection of Health Measurement Instruments) guidelines evaluated 10 validated screening tools across 43 studies involving 22,095 postpartum women. The EPDS was the only tool to receive a Class A recommendation (recommended for use), while all other tools including the PHQ-2 received Class B recommendations (further research required). 1
Key Strengths of EPDS:
- Adequate content validity with moderate evidence for sufficient internal consistency and structural validity 1
- Translated into >60 languages with demonstrated criterion validity in 10 translated versions 1
- Most robustly evaluated screening tool in postpartum populations 1
- Did not receive any insufficient ratings for psychometric properties when adequate methods were used 1
- 10 questions covering affective, behavioral, and interference domains (though notably lacks somatic symptom assessment) 1
Optimal EPDS Implementation:
- Use cutoff ≥10 for screening (maximizes sensitivity and specificity balance) 1
- Score range: 0-30, with lower scores indicating less depression
- Assesses symptoms over past 7 days 1
- Freely available for clinical use 1
Why PHQ-2 Is Insufficient as Primary Tool
While the PHQ-2 shows high sensitivity (100% in one study 2, 84% in another 3), it has critical limitations:
Major Drawbacks:
- Only 2 questions—insufficient depth for postpartum-specific symptomatology 2, 3
- Lower specificity (79%) compared to EPDS (87-92%) 2, 4
- Not specifically validated for postpartum populations in the COSMIN systematic review 1
- Detects fewer cases: 5% prevalence vs 9-13% with EPDS in comparative studies 5
- Received only Class B recommendation (not recommended as standalone) 1
Comparative Performance Data:
In a 2023 Kenyan study of 3,605 postpartum women, the PHQ-2 identified only 5% with moderate-to-severe depressive symptoms compared to 9% with EPDS and 13% with CESD-10. 5 A 2008 U.S. study found the PHQ-9 (which includes the PHQ-2 items) identified only 31% of major depressive disorder cases at 6-8 weeks postpartum, while EPDS identified 62%. 4
Clinical Algorithm
For routine postpartum depression screening:
- Administer EPDS at 6-8 weeks postpartum (can be done by phone or in-person) 4
- Score ≥10: Conduct full clinical evaluation for major depressive disorder
- Consider repeat screening at 3 and 6 months to identify emergent symptoms 4
- Positive screens require diagnostic confirmation with structured clinical interview (SCID-5) or psychiatric consultation for definitive diagnosis 1
Two-Stage Alternative (If Resources Limited):
If you must use PHQ-2 due to time constraints, employ a two-stage screening approach: 3
- Stage 1: PHQ-2 as initial screen
- Stage 2: If PHQ-2 positive → administer full EPDS for confirmation
- This approach leverages PHQ-2's high sensitivity while using EPDS's superior specificity
Important Caveats
The EPDS is a screening tool, not diagnostic. It cannot provide a definitive diagnosis of postpartum depression—only identify women at high risk who require further evaluation. 1 Sensitivity and specificity vary by cutoff used and population studied.
Timing matters but remains unclear. While most evidence supports 6-8 week screening, optimal timing for postpartum depression screening is not definitively established. 1 Consider multiple time points given that depression can emerge throughout the first postpartum year.
The EPDS lacks assessment of:
- Somatic symptoms 1
- Family relationships or infant bonding items 1
- Suicidal ideation depth (though item 10 addresses self-harm) 6
Postpartum depression is a leading cause of maternal morbidity and mortality (suicide is the second most common cause of maternal mortality in the U.S.), making accurate screening critical for reducing adverse outcomes. 1